Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
BIOC

BIOC - Biocept Inc Stock Price, Fair Value and News

0.43USD Delayed

Market Summary

BIOC
USD0.43
Delayed

BIOC Stock Price

View Fullscreen

BIOC RSI Chart

BIOC Valuation

Market Cap

183.8K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.01

EV/EBITDA

0.22

Price/Free Cashflow

-0.01

BIOC Price/Sales (Trailing)

BIOC Profitability

Operating Margin

39.43%

EBT Margin

-118.85%

Return on Equity

-10.6K%

Return on Assets

-138.48%

Free Cashflow Yield

-9.9K%

BIOC Fundamentals

BIOC Revenue

Revenue (TTM)

25.9M

BIOC Earnings

Earnings (TTM)

-30.6M

Breaking Down BIOC Revenue

Last 7 days

-40%

Last 30 days

-50%

Last 90 days

-97.9%

Trailing 12 Months

-94.8%

How does BIOC drawdown profile look like?

BIOC Financial Health

Current Ratio

1.81

BIOC Investor Care

Shares Dilution (1Y)

366.80%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
202263.4M57.2M40.7M25.9M
202143.8M54.9M65.8M61.2M
20206.0M5.7M10.7M27.5M
20193.5M3.8M4.6M5.5M
20184.2M3.7M3.4M3.3M
20174.7M5.3M5.4M5.1M
2016681.3K1.3M2.1M3.2M
2015223.0K312.7K467.2K609.9K
2014134.1K133.9K133.6K133.4K
2013134.1K128.4K136.4K134.2K
2012000109.3K

Tracking the Latest Insider Buys and Sells of Biocept Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 09, 2021
hale david f
sold
-288
4.0664
-71.00
-
Dec 09, 2021
hale david f
sold
-44.7887
4.0717
-11.00
-
Dec 09, 2021
hale david f
sold
-1,473
4.0602
-363
-
Jun 12, 2020
hale david f
sold
-308
0.555
-556
-
Jun 12, 2020
hale david f
sold
-246
0.5545
-445
-
Jun 12, 2020
hale david f
sold
-88.6902
0.5578
-159
-

1–6 of 6

Which funds bought or sold BIOC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-17,000
-
-%
Jan 25, 2022
REILLY FINANCIAL ADVISORS, LLC
new
-
1,000
1,000
-%

1–2 of 2

Are Funds Buying or Selling BIOC?

Are funds buying BIOC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIOC
No. of Funds

Unveiling Biocept Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 02, 2023
lind global fund ii lp
9.9%
147,294
SC 13G
Jan 05, 2021
sabby management, llc
12.%
0
SC 13G/A
Mar 13, 2020
intracoastal capital, llc
0.6%
607,279
SC 13G
Mar 04, 2020
sabby management, llc
12.%
0
SC 13G
Feb 14, 2020
anson funds management lp
4.8%
2,387,910
SC 13G/A
Feb 11, 2020
intracoastal capital, llc
4.5%
1,973,168
SC 13G/A
Jan 15, 2020
empery asset management, lp
4.99%
2,309,027
SC 13G/A
Jan 02, 2020
sabby management, llc
12.%
0
SC 13G/A

Peers (Alternatives to Biocept Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.9B
23.7B
11.04% 17.40%
44.73
8.29
-8.94% -35.91%
45.2B
6.7B
14.64% 19.44%
36.57
6.71
-2.81% -6.58%
44.9B
3.7B
13.71% 10.52%
51.83
12.06
8.57% 23.94%
16.0B
9.3B
13.66% 10.24%
18.95
1.73
-3.29% 6.68%
13.1B
1.2B
17.80% 114.36%
-35.76
10.81
39.26% 33.08%
12.2B
2.0B
2.71% 87.82%
38.94
6.2
25.57% 21.62%
11.4B
4.1B
-3.66% 11.24%
26.02
2.78
0.49% -11.59%
9.3B
2.5B
-20.33% -38.03%
-38.69
3.67
15.21% 53.51%
MID-CAP
3.1B
603.7M
54.73% -14.09%
-6.73
5.14
25.21% 30.68%
2.9B
929.2M
11.70% -18.80%
1.9K
3.16
28.93% 111.61%
SMALL-CAP
808.3M
275.1M
87.44% 103.94%
-4.41
2.94
-13.93% -126.97%
84.8M
31.1M
-3.25% -85.34%
-1.1
2.73
0.95% 19.75%
33.0M
9.2M
-24.07% -37.65%
-2.24
3.6
11.85% 45.80%
2.5M
5.5M
-62.31% 120.18%
-0.2
0.45
-68.52% -141.15%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Biocept Inc News

Latest updates
Yahoo New Zealand News08 May 202412:40 am
InvestorPlace11 months ago
Yahoo Finance5 years ago

Biocept Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-12.5%589,000673,000840,2501,007,5005,819,00019,945,00013,976,00017,470,00012,047,00017,756,00018,510,8386,586,144917,4711,446,5491,783,7421,529,2621,191,3231,024,239859,526761,591822,238
Cost Of Revenue-15.8%2,550,0003,028,0004,307,5005,776,0008,023,00010,334,00010,031,00011,265,0007,462,0009,006,00010,013,1015,859,3702,517,9022,946,8582,872,0982,832,7352,673,3232,599,3642,435,2622,481,9162,699,671
Costs and Expenses-13.7%6,703,0007,771,0008,875,50011,164,00015,708,00022,094,00016,751,50018,020,00013,795,00015,092,00016,544,86311,404,9297,351,1287,629,0827,434,8137,158,9967,112,6456,879,0526,797,6906,769,5746,861,100
  S&GA Expenses-65.0%250,000715,000837,500975,0001,656,0003,658,0002,514,0001,938,0001,945,0001,923,0002,167,1331,434,4811,333,2711,465,1151,489,2161,462,3351,614,7321,374,5601,440,7981,404,1921,433,174
  R&D Expenses-60.7%409,0001,040,0001,259,5001,366,0001,729,0001,846,0001,477,0001,303,0001,137,0001,043,0001,230,8671,087,7411,588,7161,312,6761,161,9051,163,5461,148,2801,223,2911,288,9571,089,7461,019,285
EBITDA Margin18.3%-1.11-1.36-1.17-0.57-0.24-0.09-0.010.06-0.01-0.12-0.60-2.25-4.41--------
Interest Expenses8.7%50,00046,00047,00052,500155,00061,00070,90574,49979,69265,00064,10959,54955,64656,69662,40962,02863,57461,97480,29963,76484,239
Income Taxes-------------------1,147--
Earnings Before Taxes49.2%-3,631,000-7,144,000-9,833,000-10,125,000-10,044,000-2,210,000-2,845,500-625,000-1,828,0002,599,0001,901,975-4,878,334-6,489,303-8,341,338-5,713,479-5,691,762-7,816,012-5,916,787-6,012,426-6,047,784-6,153,101
EBT Margin17.3%-1.19-1.44-1.25-0.62-0.27-0.12-0.040.03-0.04-0.16-0.65-2.37-4.62--------
Net Income49.2%-3,631,000-7,144,000-9,708,000-10,125,000-10,044,000-2,210,000-2,971,000-625,000-1,827,0002,599,00012,284,649,821-4,878,334,000-6,489,303-8,341,338-5,713,478-5,691,762-7,816,012-5,916,787-6,014,312-6,047,784-6,153,101
Net Income Margin17.3%-1.18-1.43-1.24-0.62-0.28-0.12-0.05186134169269-456-4.62--------
Free Cashflow49.4%-3,183,000-6,285,000-4,378,000-4,431,000-4,257,000-1,030,000974,000-835,0001,847,000132,000-1,904,568-6,742,609-6,708,456--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-3.9%22.0023.0031.0042.0053.0062.0060.0062.0051.0050.0047.0033.0033.0030.0018.0015.0020.0022.009.0015.008.00
  Current Assets-2.5%9.009.0016.0027.0039.0048.0046.0047.0036.0035.0033.0029.0029.0026.0014.0011.0016.0017.006.0012.005.00
    Cash Equivalents-2.1%7.007.0013.0018.0023.0028.0029.0028.0020.0014.0014.0017.0024.0021.009.007.0013.0015.003.009.003.00
  Inventory-21.7%1.001.001.002.002.003.003.003.003.003.002.003.001.001.001.001.001.001.001.001.001.00
  Net PPE-4.7%2.003.003.003.003.002.002.002.002.002.002.002.001.001.002.001.001.001.003.003.003.00
Liabilities6.1%22.0021.0022.0024.0026.0025.0023.0023.0021.0024.0024.0011.007.007.007.007.007.008.006.006.006.00
  Current Liabilities11.6%5.004.006.007.0010.0014.0012.0011.0010.0012.0012.0010.006.006.006.006.006.006.005.004.005.00
Shareholder's Equity-88.1%0.002.009.0018.0028.0037.0037.0039.0029.0027.0024.0021.0026.0023.0011.008.0013.0014.003.009.003.00
  Retained Earnings-1.2%-309-305-298-288-278-268-266-263-262-260-263-265-260-254-245-239-234-226-220-214-207
  Additional Paid-In Capital0.5%310308307307306306304302292288287287287277257248247240223223210
Shares Outstanding306.0%2.001.001.001.001.001.001.001.000.000.000.000.000.00--------
Float-----16.00---60.00---93.00---26.00---14.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations50.2%-3,086-6,194-4,242-4,075-4,040-9321,564-6851,967844-1,115-6,713-6,691-5,278-5,471-5,607-6,722-5,247-5,418-5,454-5,906
  Share Based Compensation-33.9%2093164214625851,759807701494460437167194143245298225102111113174
Cashflow From Investing75.8%-22.00-91.00-136-356-217-98.00-590-150-120-712-802-28.87-16.95-18.51-437-211-53.58-32.90--72.90-18.38
Cashflow From Financing1731.5%2,967162-746-476-381-2681929,0823,406-302-584-4529,26917,4898,671-2324,60416,619-11411,915-778
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BIOC Income Statement

2023-06-30
Condensed Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Net revenues$ 589$ 5,819$ 1,262$ 25,763
Costs and expenses:    
Cost of revenues2,5508,0235,57818,357
Research and development expenses4091,7291,4493,574
General and administrative expenses3,4944,3006,48210,556
Sales and marketing expenses2501,6569655,314
Total costs and expenses6,70315,70814,47437,801
Loss from operations(6,114)(9,889)(13,212)(12,038)
Other income (expense):    
Interest expense, net(50)(155)(96)(217)
Other income, net91 91 
Change in fair value of warrant liability2,442 2,442 
Total other income (expense):2,483(155)2,437(217)
Loss before income taxes(3,631)(10,044)(10,775)(12,255)
Net loss(3,631)(10,044)(10,775)(12,255)
Net loss attributable to common stockholders$ (3,631)$ (10,044)$ (10,775)$ (12,255)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders:    
Basic1,036,529563,528813,180562,561
Diluted1,036,529563,528813,180562,561
Net loss per common share:    
Basic$ (3.50)$ (17.82)$ (13.25)$ (21.78)
Diluted$ (3.50)$ (17.82)$ (13.25)$ (21.78)

BIOC Balance Sheet

2023-06-30
Condensed Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash$ 6,633$ 12,897
Accounts receivable8002,151
Inventories, net551757
Prepaid expenses and other current assets876538
Total current assets8,86016,343
Fixed assets, net2,3952,572
Lease right-of-use asset - operating8,1908,486
Lease right-of-use assets - finance2,2723,086
Other non-current assets386386
Total assets22,10330,873
Current liabilities:  
Accounts payable1,4671,523
Accrued liabilities1,5292,249
Current portion of lease liability - operating565518
Current portion of lease liabilities - finance8151,099
Financed insurance premiums526117
Total current liabilities4,9025,506
Non-current portion of lease liability - operating8,8499,175
Non-current portion of lease liabilities - finance8361,200
Payor liability6,1496,132
Warrant liability1,077 
Total liabilities21,81322,013
Commitments and contingencies (see Note 11)
Stockholders' equity:  
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; 2,090 shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, $0.0001 par value, 150,000,000 shares authorized; 2,407,381 shares and 568,994 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively.
Additional paid-in capital309,503307,298
Accumulated deficit(309,213)(298,438)
Total stockholders' equity2908,860
Total liabilities and stockholders' equity$ 22,103$ 30,873
BIOC
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://biocept.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES50

Biocept Inc Frequently Asked Questions


What is the ticker symbol for Biocept Inc? What does BIOC stand for in stocks?

BIOC is the stock ticker symbol of Biocept Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biocept Inc (BIOC)?

As of Tue Dec 26 2023, market cap of Biocept Inc is 183.82 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIOC stock?

You can check BIOC's fair value in chart for subscribers.

What is the fair value of BIOC stock?

You can check BIOC's fair value in chart for subscribers. The fair value of Biocept Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biocept Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIOC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biocept Inc a good stock to buy?

The fair value guage provides a quick view whether BIOC is over valued or under valued. Whether Biocept Inc is cheap or expensive depends on the assumptions which impact Biocept Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIOC.

What is Biocept Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 26 2023, BIOC's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIOC PE ratio will change depending on the future growth rate expectations of investors.